To the Editor:

To date, acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is an ongoing pandemic; it is rapidly spreading and influencing human living [1]. Trans-membrane protease serine 2 (TMPRSS2) and angiotensin-converting enzyme 2 (ACE2) as host factors play a role in the pathogenesis of SARS-CoV-2 infection [2]. High expression of both ACE2 and TMPRSS2 was observed in the thyroid gland [3]. Some evidence supports the association between SARS-CoV-2 infection and thyroid malfunctions, such as nonthyroidal illness syndrome, thyrotoxicosis, hypothyroidism, and subacute thyroiditis [3–6]. Moreover, this infection may act as a promoter of thyroid-related autoimmune disease [7].

Thyroid dysfunction and lack of estrogen in menopausal transition are associated with several morbidities that reduce the quality of life of the affected. It has been shown that thyroid dysfunction may be resulted in cognitive impairment, depression, disability, loss in bone mineral density (BMD), osteoporosis, and fracture risk [16, 17]. In addition to an impairment in quality of life [18], menopause is associated with cardiovascular/metabolic risk, cognition problems, and bone mineral density (BMD) loss [19–22]. Considering the aggregation of thyroid dysfunction with SARS-CoV-2 infection [10], it assumed that all these adverse effects of thyroid dysfunction and estrogen deficiency may be increased during this hard period of the COVID-19 pandemic.

Taken as a whole, it can be concluded that viral infection due to the SARS-CoV-2 possibly affects the thyroid gland in women during the menopausal transition and postmenopausal period. Due to the possible bidirectional association between thyroid function and climacteric symptoms and thyroid function and SARS-CoV-2 infection, it is hypothesized that SARS-CoV-2 may alter growing future morbidities due to the worsen thyroid problems and climacteric symptoms in women during menopausal transition.

There are some questions that remain yet to be answered in future studies:

Could climacteric symptoms be hiding a thyroid problem due to the SARS-CoV-2 infection?

Does thyroid dysfunction related to the SARS-CoV-2 infection act as a promoter of climacteric symptoms?

Does thyroid dysfunction related to the SARS-CoV-2 infection worsen the physiological changes of thyroid function and climacteric symptoms?

Does thyroid dysfunction related to the SARS-CoV-2 infection worsen health outcomes related to the climacteric symptoms?

Summary of Recommendations:

To investigate the possible association between SARS-CoV-2 infection, thyroid function, and climacteric symptoms.
To investigate the severity of climacteric symptoms in women who are infected by SARS-CoV-2 infection.

To take extra attention in women infected by SARS-CoV-2 infection during menopause, perimenopause, and postmenopausal period especially those at risk of thyroid disease.

To watchful management of thyroid dysfunction symptoms and climacteric symptoms during the menopausal transition.

Declarations

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent Not applicable.

Disclosure of interests No conflict of interest to disclose.

References

1. Liu Y-C, Kuo R-L, Shih S-R. COVID-19: The first documented coronavirus pandemic in history. Biomed J. 2020;43(4):328–33.

2. Senapati S, Banerjee P, Bhagavatula S, Kushwaha PP, Kumar S. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction in COVID-19. J Genet 2021;100(12).

3. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: an update. Rev Endocr Metab Disord 2020;1-13.

4. Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazzotti G. Thyrotoxicosis in patients with COVID-19: the THYRCOV study. Eur J Endocrinol. 2020;183(4):381–7.

5. Brancatella A, Ricci D, Cappellani D, Viola N, Sgrò D, Santini F, Latrofa F. Is subacute thyroiditis an underestimated manifestation of SARS-CoV-2 infection? Insights from a case series. J Clin Endocrinol Metab. 2020;105(10):dgaa537.

6. Sohrabpour S, Heidari F, Karimi E, Ansari R, Tajdini A, Heidari F. Subacute thyroiditis in COVID-19 patients. Eur Thyroid J. 2020;9(6):322–4.

7. Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19. J Endocrinol Invest. 2020;43(10):1527–8.

8. Ajish TP, Jayakumar RV. Geriatric thyroidology: An update. Indian J Endocrinol Metab. 2012;16(4):542–7.

9. Gesing A, Lewiński A, Karbowik-Lewińska M. The thyroid gland and the process of aging; what is new? Thyroid Res. 2012;5(1):1–5.

10. Kumari K, Chainy GB, Subudhi U. Prospective role of thyroid disorders in monitoring COVID-19 pandemic. Heliyon 2020:e05712.

11. Gietka-Czernel M. The thyroid gland in postmenopausal women: physiology and diseases. Przegl Menopauzalny= Menopause review 2017;16(2): 33.

12. Panda S, Das A. Analyzing thyroid dysfunction in the climacteric. J Mid-Life Health. 2018;9(3):113.

13. Ali AM, Ahmed AH, Smail L. Psychological climacteric symptoms and attitudes toward menopause among Emirati women. Int J Environ Res Public Health. 2020;17(14):5028.

14. Badawy A, State O, Sherief S. Can thyroid dysfunction explain severe menopausal symptoms? J Obstet Gynaecol. 2007;27(5):503–5.

15. Slopian R, Owecki M, Slopian A, Bala G, Meczekalski B. Climacteric symptoms are related to thyroid status in euthyroid menopausal women. J Endocrinol Investig. 2020;43(1):75–80.

16. Agarwal N, Razvi S. Thyroid and aging or the aging thyroid? An evidence-based analysis of the literature. J Thyroid Res 2013;2013.

17. Chaker L, Cappola AR, Mooijaart SP, Peeters RP. Clinical aspects of thyroid function during ageing. Lancet Diabetes Endocrinol. 2018;6(9):733–42.

18. Szadowska-Szlachetka ZC, Stasiak E, Leziak A, Irazmańska-Hudziak A, Łuczyk M, Stanisławek A, Słusarska B, Domżał-Drzewicka R. Intensity of menopausal symptoms and quality of life in climacteric women. Przegl Menopauzalny= Menopause review 2019;18(4): 217.

19. Maas AH, Rosano G, Cifkova R, Chieffo A, van Dijken D, Hamoda H, Kunadian V, Laan E, Lambrinoudaki I, Maclaran K. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J. 2021;42(10):967–84.

20. Ji M-X, Yu Q. Primary osteoporosis in postmenopausal women. Chron Dis Transl Med. 2015;1(1):9.

21. Gray KE, Katon JG, LeBlanc ES, Woods NF, Bastian LA, Reiber GE, Weitlauf JC, Nelson KM, LaCroix AZ. Vasomotor symptom characteristics: are they risk factors for incident diabetes? Menopause (New York, NY). 2018;25(5):520.

22. Guva G, Olsili I, Alvisi S, Mancini I, Seracchioli R, Meriggiola MC. Cognition, mood and sleep in menopausal transition: the role of menopause hormone therapy. Medicina. 2019;55(10):668.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.